uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
Show others and affiliations
2010 (English)In: BMC Cancer, ISSN 1471-2407, Vol. 10, 125- p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer. METHODS: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS). RESULTS: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade. CONCLUSION: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens.

Place, publisher, year, edition, pages
2010. Vol. 10, 125- p.
National Category
Obstetrics, Gynecology and Reproductive Medicine Cell and Molecular Biology
Research subject
Pathology; Obstetrics and Gynaecology
URN: urn:nbn:se:uu:diva-126030DOI: 10.1186/1471-2407-10-125ISI: 000276817100001PubMedID: 20359358OAI: oai:DiVA.org:uu-126030DiVA: diva2:321644
Available from: 2010-06-01 Created: 2010-06-01 Last updated: 2010-12-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Genetics and Pathology
In the same journal
BMC Cancer
Obstetrics, Gynecology and Reproductive MedicineCell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 188 hits
ReferencesLink to record
Permanent link

Direct link